Episurf Medical publishes prospectus in connection with the company's partially guaranteed rights issue of up to approximately SEK 120 million
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
On 22 April 2024, Episurf Medical AB (publ) ("Episurf", "Episurf Medical" or the "Company"), (NASDAQ Stockholm: EPIS B) announced that the Board of Directors had, subject to the subsequent approval by an Extraordinary General Meeting (the "EGM"), resolved on a new issue of units with preferential rights for existing shareholders of up to approximately SEK 120 million before deduction of costs attributable to the rights issue (the "Rights Issue"). The Rights Issue is covered to approximately 75 percent, corresponding to approximately SEK 90 million, by subscription commitments and intentions as well as guarantee commitments. The Board of Directors' resolution on the Rights Issue was approved by the EGM held on 22 May 2024. A prospectus that has been prepared in connection with the Rights Issue has today, 24 May 2024, been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) ("SFSA") and is available in Swedish on Episurf's website https://episurf.com/, as well as on Pareto Securities' website www.paretosec.com.
Publication of the prospectus
Complete information about the Rights Issue is included in the prospectus that has been prepared by the Board of Directors of the Company and that today, 24 May 2024, has been approved and registered by the SFSA. The prospectus in Swedish is available on the Company's website (https://episurf.com/) and on Pareto Securities' website (www.paretosec.com). The prospectus will also be available in Swedish on SFSA's website (www.fi.se/sv/vara-register/prospektregistret/).
Application forms
The subscription period will commence on 28 May 2024. Subscription forms for subscription without preferential rights will be available on the Company's, Pareto Securities' and Nordic Issuing AB's respective websites. Subscription for units without preferential rights can also be made with Swedish BankID or Nordic eID via www.minasidor.nordic-issuing.se.
Timetable of the Rights Issue
24 May Record date for receipt of unit rights
2024
24 May Publication of the prospectus
2024
28 May - 7 Trading in unit rights
June 2024
28 May - Subscription period
12 June
2024
28 May - Trading in BTUs (paid subscribed units)
24 June
2024
13 June Expected announcement of the outcome of the
2024 Rights Issue
28 June Expected first day of trading in warrants of
2024 series TO13 B on Nasdaq First North Growth
Market
10 - 24 Exercise period for warrants of series TO13 B
February
2025
Advisors
Pareto Securities has been appointed as Sole Manager and Bookrunner in the Rights Issue. Hannes Snellman Advokatbyrå AB is legal adviser to Episurf in connection with the Rights Issue. Advokatfirman Vinge KB is legal adviser to the Sole Manager and Bookrunner in connection with the Rights Issue. Nordic Issuing acts as issuing agent in connection with the Rights Issue.